1. Home
  2. OPP vs CBIO Comparison

OPP vs CBIO Comparison

Compare OPP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPP
  • CBIO
  • Stock Information
  • Founded
  • OPP 2010
  • CBIO 2003
  • Country
  • OPP United States
  • CBIO United States
  • Employees
  • OPP N/A
  • CBIO N/A
  • Industry
  • OPP Finance/Investors Services
  • CBIO
  • Sector
  • OPP Finance
  • CBIO
  • Exchange
  • OPP Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • OPP 208.6M
  • CBIO 173.5M
  • IPO Year
  • OPP N/A
  • CBIO N/A
  • Fundamental
  • Price
  • OPP $8.65
  • CBIO $12.22
  • Analyst Decision
  • OPP
  • CBIO Strong Buy
  • Analyst Count
  • OPP 0
  • CBIO 5
  • Target Price
  • OPP N/A
  • CBIO $25.60
  • AVG Volume (30 Days)
  • OPP 108.0K
  • CBIO 107.5K
  • Earning Date
  • OPP 01-01-0001
  • CBIO 07-31-2025
  • Dividend Yield
  • OPP 14.41%
  • CBIO N/A
  • EPS Growth
  • OPP N/A
  • CBIO N/A
  • EPS
  • OPP N/A
  • CBIO N/A
  • Revenue
  • OPP N/A
  • CBIO N/A
  • Revenue This Year
  • OPP N/A
  • CBIO N/A
  • Revenue Next Year
  • OPP N/A
  • CBIO N/A
  • P/E Ratio
  • OPP N/A
  • CBIO N/A
  • Revenue Growth
  • OPP N/A
  • CBIO N/A
  • 52 Week Low
  • OPP $7.26
  • CBIO $10.83
  • 52 Week High
  • OPP $8.83
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • OPP 46.78
  • CBIO 39.28
  • Support Level
  • OPP $8.70
  • CBIO $12.09
  • Resistance Level
  • OPP $8.78
  • CBIO $14.50
  • Average True Range (ATR)
  • OPP 0.07
  • CBIO 0.93
  • MACD
  • OPP -0.00
  • CBIO -0.19
  • Stochastic Oscillator
  • OPP 34.62
  • CBIO 3.45

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: